Tourmaline Bio, Inc.
September 09, 2025 - by Joey Ramson
$TRML has been acquired by Novartis for $48 per share. Tourmaline is focused on developing pacibekitug, a targeted therapy to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease.
